<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02487732</url>
  </required_header>
  <id_info>
    <org_study_id>Adenosine diphosphate blockers</org_study_id>
    <nct_id>NCT02487732</nct_id>
  </id_info>
  <brief_title>Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <brief_summary>
    <textblock>
      To investigate pleiotropic effects of ticagrelor in addition to its antiplatelet effects in&#xD;
      type 2 diabetic patients with non-ST elevation acute coronary syndrome by measuring&#xD;
      inflammatory markers, circulating number of endothelial progenitor cells, brachial artery&#xD;
      endothelial function, and arterial stiffness.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in circulating number of endothelial progenitor cells</measure>
    <time_frame>Expected average of 5 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in brachial artery flow mediated dilation</measure>
    <time_frame>Expected average of 5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite measure of brachial-ankle pulse wave velocity, and augmentation index.</measure>
    <time_frame>Expected average of 5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>180mg loading dose, 90mg twice daily for 5 weeks, then crossover to prasugrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60mg loading dose, 10mg once daily for 5 weeks, then crossover to ticagrelor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 90mg twice daily for 5 weeks</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Prasugrel 10mg once daily for 5 weeks</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>Effient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
          2. Newly diagnosed type 2 diabetic patients or type 2 diabetic patients on hypoglycemic&#xD;
             agents between the age of 30 to 70&#xD;
&#xD;
          3. Non-ST elevation Acute coronary syndrome with successful coronary stent implantation&#xD;
             (with TIMI flow grade 3 after the procedure)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to ticagrelor, prasugrel or any of the excipients&#xD;
&#xD;
          2. No prior use of either ticagrelor or prasugrel within a month prior to randomization.&#xD;
&#xD;
          3. History of intracranial bleeding at any time&#xD;
&#xD;
          4. Active pathologic bleeding&#xD;
&#xD;
          5. Hemoglobin A1c &gt;9%&#xD;
&#xD;
          6. Type 1 diabetes&#xD;
&#xD;
          7. Decreased serum platelet level (&lt; 100,000/uL)&#xD;
&#xD;
          8. Need for chronic oral anticoagulant therapy or chronic low-molecular-weight heparin&#xD;
&#xD;
          9. Gastrointestinal bleed within the past 6 months, or major surgery within 30 days&#xD;
&#xD;
         10. Renal failure requiring dialysis or anticipated need for dialysis during the course of&#xD;
             the study&#xD;
&#xD;
         11. Any condition which in the opinion of the investigator would make it unsafe or&#xD;
             unsuitable for the patient to participate in this study&#xD;
&#xD;
         12. Involvement in the planning and/or conduct of the study&#xD;
&#xD;
         13. Left ventricular ejection fraction &lt; 40%&#xD;
&#xD;
         14. Hepatic dysfunction (aspartate aminotransferase or alanine aminotransferase &gt; twice&#xD;
             the upper limit)&#xD;
&#xD;
         15. Gastrointestinal disorder such as Crohn's disease&#xD;
&#xD;
         16. Alcohol abuse&#xD;
&#xD;
         17. Steroid or hormone replacement therapy&#xD;
&#xD;
         18. Serum creatinine &gt; 2.0 mg/dL.&#xD;
&#xD;
         19. Prior history of CVA or stroke&#xD;
&#xD;
         20. Body weight &lt; 60 kg&#xD;
&#xD;
         21. Life expectancy less than a year&#xD;
&#xD;
         22. Known pregnancy, breast-feeding, or intend to become pregnant during the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>June 27, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>April 24, 2019</last_update_submitted>
  <last_update_submitted_qc>April 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Soon Jun Hong</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetic Patients With Non-ST Elevation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

